Fig. 1

a and b Overall Survival (OS) (Fig. a) and Event-free Survival (EFS) of 683 AML patients dichotomized to the LOX-high (n = 272) and LOX-low (n = 411) group. LOX-high patients are denoted in green, LOX-low patients are denoted in blue color. The logarithmic logLOX value = 2.0403 (109 ng/mL) was used to dichotomize all patients in both groups, respectively. For LOX-high patients 3-year OS was 47% (95% CI, 40–53%) and for LOX-low patients 53% (95% CI, 48–58%), p = .022. Three-year EFS for LOX-high patients was 27% (95% CI, 21–32%) and for LOX-low patients 35% (95% CI, 30–40%), p = 0.005